Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
MDAI have just delivered the following guidance
Financial Guidance
* Research & Development Revenue (“Revenue”) for FY2023 is expected to
approximate $17.4 million
* Revenue for FY2024 is expected to approximate $28.0 million
“We are on the cusp of delivering a distinct, cutting-edge AI-driven wound
healing assessment platform with the potential to significantly improve the
current standard of care across multiple indications,” said Wensheng Fan,
CEO of Spectral AI. “As we continue to advance our burn indication, we are
as excited about the prospects for the use of DeepView(®) for DFU, an
estimated $11.0 billion market that we believe is in dire need of a solution
that provides clinicians with an immediate healing assessment for more
accurate and timely diagnosis and therapeutic intervention. We intend to
submit applications for FDA, UKCA, and CE mark approval for the DeepView(®)
DFU indication, as well as for 3D wound measurement capabilities, in FY2024
subject to the completion of ongoing studies.”
The Company noted that the financial guidance for FY2024 does not reflect the
material financial contributions it expects would result from the
commercialization of DeepView(®) for DFU and 3D wound measurement following
the receipt of necessary regulatory clearances. As previously disclosed, the
Company has received regulatory approval for the DeepView SnapShot(®) device
and the Company will now seek the approval of its integrated AI application to
obtain both UKCA and FDA approval for the commercialization of the complete
DeepView SnapShot(®) System in the United States and across the globe.
“We believe we are in the best position in our history to deliver
significant value for patients dealing with acute and chronic wound
conditions, physicians and health systems that are challenged with effectively
and cost-efficiently managing these conditions, and, of course, our
shareholders,” Mr. Fan concluded.
As expected encouraging Financial Guidence as I anticipate the Company going from strength to strength over the coming weeks, months and years with the brilliant devices that they have now and for which there will be demand globally, I am sure, in the fullness of time. However, I do wonder if a mistake was made by leaving AIM but time will tell though I know that I shall never go near Nasdaq again. I was pleased to see that shareholders were mentioned in the report. I am still awaiting MDAI shares after 6 weeks!
Has everyone got their shares?
Looks like they are still naked shorting it. Unbelievable!
No. Rang up ii last week and they said there had been a problem at their end but this had now been resolved and the shares should be with me early this week, but still nothing.
I've had mine (through Halifax Share Dealing) for a couple of weeks now - it's quite unbelievable in these modern times that people are waiting on paper transactions for what could be significant financial issues, and all we have been able to do is stare forlornly at a screen which is literally dissolving our investment. I long for a day when the Shorters (naked or otherwise) move on and leave us to see what this can actually do.